P-265: Treatment patterns and outcomes of patients with triple-class exposed relapsed or refractory multiple myeloma: analysis of the Optum electronic health records and commercial claims database
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with triple-class-exposed relapsed and refractory multiple myeloma, conventional therapies yield poor prognosis, with median progression-free survival of approximately 3 to 5 months and median overall survival of approximately 9 to 22 months.
“Prognosis is poor with conventional therapies, with a median progression-free survival (PFS) of ~3 to 5 months and a median overall survival (OS) of ~9 to 22 months in this patient population. 5-12”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [8]
There is no standard of care for early triple-class-exposed relapsed and refractory multiple myeloma.
“Management of relapsed MM remains challenging; patients are becoming triple-class exposed (TCE) earlier in their treatment course, 4-8 with no standard of care for early TCE relapsed and refractory MM (R/RMM).”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [8]
Cites
Still being checked.
Cited by
Sorted by citations
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781 · see citing works
Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood · doi:10.1182/blood.2024024582 · Cited by 79 · see citing works
Nadeem, O., Ailawadhi, S., Khouri, J., Williams, L. S., Catamero, D., Maples, K. T., & Berdeja, J. G. (2024) · Cancers · doi:10.3390/cancers16051023 · Cited by 9 · see citing works
- Authors
- Kumar, S., Nair, S., Lin, X., Marshall, A., Slavcev, M., Potluri, R., & Chari, A.
- Venue
- Clinical Lymphoma Myeloma and Leukemia
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 22
- Pages
- S183
- ISSN
- 2152-2650 (ISSN-L)
- OpenAlex
- W4293107897
- Cited by
- 3
- References
- 0
- Citations by year
- 2024: 2 · 2023: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Clinical Lymphoma Myeloma & Leukemia (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- multiple myeloma, relapsed/refractory multiple myeloma, treatment patterns, treatment outcomes, electronic health records
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
